Treace Medical Concepts, Inc.

Name: Treace Medical Concepts, Inc. standardized financial statements, quarterly
Creator: Listed

TMCINasdaqCIK 1630627HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$45.4m, Q2 FY2026

Operating income−$15.0m, Q2 FY2026

Net income−$15.9m, Q2 FY2026

Treace Medical Concepts, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	40.8	62.2	51.1	44.5	45.1	68.7	52.6	47.4	50.2	62.5	47.2	45.4
Cost of revenue	$m	8.0	11.5	10.1	8.8	9.0	13.2	10.7	9.6	10.5	12.1	9.8	9.8
Gross profit	$m	32.8	50.7	41.0	35.7	36.1	55.5	41.9	37.8	39.7	50.4	37.4	35.6
Research and development	$m	4.4	4.2	5.3	5.2	5.0	5.2	5.6	5.5	4.7	4.5	4.6	4.4
Operating income	$m	(17.8)	(6.8)	(19.0)	(21.4)	(15.1)	(0.2)	(15.6)	(17.0)	(15.7)	(5.9)	(17.2)	(15.0)
Interest expense	$m	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.6	1.6
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(17.5)	(6.3)	(18.7)	(21.2)	(15.4)	(0.5)	(15.9)	(17.4)	(16.3)	(9.4)	(18.0)	(15.9)
Diluted EPS	$ per share	(0.28)	not reported	(0.30)	(0.34)	(0.25)	not reported	(0.25)	(0.28)	(0.26)	not reported	(0.28)	(0.24)
Basic EPS	$ per share	(0.28)	not reported	(0.30)	(0.34)	(0.25)	not reported	(0.25)	(0.28)	(0.26)	not reported	(0.28)	(0.24)

Balance sheet

Cash and equivalents$12.6m, Q2 FY2026

Long-term debt$56.0m, Q2 FY2026

Shareholders' equity$67.7m, Q2 FY2026

Treace Medical Concepts, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	7.3	13.0	9.3	18.2	12.1	11.4	13.4	8.1	7.7	10.7	9.5	12.6
Current assets	$m	187	198	187	172	158	161	149	148	138	132	123	120
Total assets	$m	240	252	243	226	213	217	206	206	197	191	184	181
Current liabilities	$m	33.2	45.0	47.0	44.4	38.3	34.9	33.2	41.9	40.9	30.6	34.5	41.5
Total liabilities	$m	103	114	116	114	108	104	101	109	107	103	107	113
Long-term debt	$m	52.9	53.0	53.1	53.2	53.2	53.3	53.4	53.5	53.5	55.6	55.8	56.0
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	not reported	not reported	not reported	not reported	not reported	0.0	0.0	1.1	1.8	1.7	1.8	3.2
Shareholders' equity	$m	138	138	126	112	105	113	105	97.6	89.2	87.3	77.2	67.7

Cash flow

Operating cash flow−$4.7m, Q2 FY2026

Capital expenditure$2.2m, Q2 FY2026

Treace Medical Concepts, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(9.5)	0.5	(7.2)	(13.9)	(11.8)	(4.2)	4.2	(3.1)	(9.1)	(8.0)	7.2	(4.7)
Capital expenditure	$m	3.5	2.2	3.9	1.7	2.9	3.1	3.5	4.8	2.8	2.4	3.1	2.2

Diluted shares (weighted)65.05m, Q2 FY2026

Treace Medical Concepts, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	55.4	58.7	61.4	61.6	61.8	62.1	62.2	62.7	63.0	63.5	64.6	65.0

Shares outstanding: 65.03m at Jul 31, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.